Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Ocean Power Technologies (NYSE American: OPTT) has successfully delivered its WAM-V® unmanned surface vehicle to Stevens Institute of Technology, marking completion of the customer order announced in June 2026. The delivery was completed in five weeks, highlighting OPT's enhanced manufacturing and operational capabilities. This milestone underlines…
U.S. equity futures advanced on Thursday after Microsoft posted a robust fiscal fourth-quarter beat and signaled its AI investments are translating into demand. Gains were restrained by a hawkish Federal Reserve tone and rising oil prices amid escalating Middle East conflict. Individual corporate results produced volatile premarket moves, with Quan…
Monster Beverage Corporation will release its financial results for the second quarter ended June 30, 2026, on August 6, 2026, followed by a conference call hosted by CEO Hilton Schlosberg to discuss financial performance and business operations. The call will be accessible via live webcast.
Cellectar Biosciences, a late-stage clinical biopharmaceutical company focused on cancer drug development, will report its second quarter 2026 financial results and provide a corporate update on August 13, 2026. The company is developing several targeted cancer therapies using its proprietary Phospholipid Drug Conjugate platform, with multiple FDA …
Weeks after the June 24 twin earthquakes that struck Venezuela’s central coast, survivors are relocating inland to escape persistent aftershocks and trauma. Adriana Aponte, a 26-year-old mother of three, moved from La Guaira to the oil-producing city of Maracaibo with help from relatives. The disaster killed at least 5,500 people, displaced tens of…
Regeneron Pharmaceuticals surged in pre-market trading after reporting second-quarter 2026 results that significantly outpaced analyst forecasts. Adjusted EPS of $14.29 topped consensus by $3.71, and revenue of $4.29 billion beat expectations by a wide margin. Record sales across key franchises and the full repayment of the Sanofi Development Balan…
China's Politburo convened a mid-year meeting to review economic policy, issuing a statement that struck a constructive tone but stopped short of announcing fresh measures. The readout removed earlier language describing major indicators as "better than expected," reiterated support for new growth drivers and an improving economic structure, and sa…
Gulf Arab states are pressing China to use its economic relationship with Iran to ensure the safe passage of oil and commercial shipping through the Strait of Hormuz and the Red Sea. Beijing has engaged diplomatically through senior envoys and ministerial contacts, but Gulf officials and analysts question how far China will go to exert pressure on …
Regeneron reported second-quarter revenue and profit that exceeded Wall Street expectations, driven by robust global sales of Dupixent and rising uptake of a higher-dose formulation of Eylea in the U.S. The company also completed repayment of an outstanding development balance to Sanofi, a move cited as supportive of margin improvement for the rema…
CytomX Therapeutics, a clinical-stage biopharmaceutical company focused on conditionally activated biologics for oncology, will release its Q2 2026 financial results on August 6, 2026. The company will also host a conference call and webcast to discuss the results. CytomX continues to develop its pipeline of novel therapies including antibody-drug …
PolyPid Ltd., a biopharmaceutical company focused on localized drug delivery systems, announced it will release its Q2 2026 financial results and operational highlights on August 12, 2026, with a conference call and webcast scheduled to discuss the update.
GigaCloud Technology Inc, a Nasdaq-listed B2B ecommerce technology company specializing in global end-to-end solutions for large parcel merchandise, announced it will release its financial results for the second quarter ended June 30, 2026, on August 6 before market open, followed by a conference call at 8:00 AM ET.
PetMed Express, a leading online pet pharmacy, will release its financial results for the first quarter ended June 30, 2026, on August 13, 2026. The company will hold a conference call and webcast to discuss the results. PetMed Express operates nationally and offers a wide range of pet healthcare products through its PetMeds and PetCareRx brands.
Intellia Therapeutics, a leader in CRISPR gene editing therapies, announced it will hold a conference call on August 6, 2026, to discuss its second quarter financial results and provide updates on its business. The company continues to focus on developing potentially curative treatments for severe diseases leveraging gene editing technologies.
Abercrombie & Fitch introduces its Fall 2026 denim collection titled "Denim Made Iconic," emphasizing the brand's New York City roots and heritage. The campaign features noted personalities from fashion and sports and highlights new denim silhouettes aiming to blend style, comfort, and authenticity. The collection will be available online and in st…
Euronet Worldwide announced its second quarter 2026 financial results, highlighting a 3% revenue increase to $1.108 billion and a 10% increase in adjusted earnings per share to $2.82. The company demonstrated strong growth in its digital accelerator revenue, which increased 31% year over year and represented 26% of total revenues. Strategic initiat…
Immutep Limited provided its Q4 FY26 activities update, highlighting positive pooled analysis results from efti trials demonstrating a 7.7-month median overall survival benefit in responders across multiple cancers. However, the Phase III TACTI-004 trial in first-line NSCLC was discontinued due to futility. Encouraging Phase I results were presente…
Iovance Biotherapeutics, a biotechnology firm specializing in tumor infiltrating lymphocyte (TIL) therapies for cancer, will report its Q2 2026 financial results and corporate updates on August 6, 2026. The company is a leader in TIL therapy innovation, with its Amtagvi® therapy approved by the FDA for solid tumors. The webcast aims to provide inve…
ASP Isotopes Inc. announced that its Chief Commercial Officer will present at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The company focuses on advanced isotope enrichment technologies for critical materials in sectors such as nuclear medicine, semiconductors, and nuclear energy. Additionally, ASP Isotopes is involved i…
ZenaTech, Inc. announced the acquisition of Velocity Geomatics, a drone-based surveying and regulatory compliance service provider for the oil and gas sector in Western Canada. This move expands ZenaTech's Drone as a Service (DaaS) business amid a favorable market, supported by a 45% year-over-year increase in crude oil prices and over $500 billion…
Aprea Therapeutics updates clinical progress on APR-1051, its oral WEE1 inhibitor, reporting accelerated enrollment and plans to expand development into combination regimens for multiple biomarker-defined cancers. The company anticipates presenting new Phase 1 data from ACESOT-1051 in Q4 2026, supporting further dose escalation and development in u…
Verrica Pharmaceuticals will report its second quarter 2026 financial results on August 6, 2026, and provide a corporate update via conference call and webcast. The company focuses on dermatological disease treatments, including FDA-approved YCANTH® for molluscum contagiosum and pipeline products targeting common warts and non-melanoma skin cancers…
Uniti Group Inc. announced its second quarter 2026 financial results, highlighting record new bookings at its Fiber Infrastructure segment and strong growth in Kinetic Consumer Fiber revenue and subscriber base. The company updated its full-year 2026 outlook with consolidated revenue expected between $3.63 billion and $3.68 billion, and adjusted EB…
MIRA Pharmaceuticals announced significant progress in the preclinical development of its two lead oral small-molecule drug candidates: MIRA-55 for chronic inflammatory pain and SKNY-1 for obesity and addiction-related disorders. The company has advanced formulation optimization, chemistry, manufacturing, controls, and exploratory toxicology studie…
VirTra, a leader in immersive simulation-based training, announced its acceptance into the U.S. Army Marketplace across three critical capability areas: Weapons Skills Development, Joint Fires Training, and Counter-Unmanned Aircraft Systems. This inclusion allows VirTra to compete for future Army contracts and highlights the Army's recognition of V…
